# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Joseph Pantginis reiterates Tempest Therapeutics (NASDAQ:TPST) with a Buy and maintains $47 ...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Tempest Therapeutics (NASDAQ:TPST) with a Buy and maintains $47 ...
Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of ...
Shares of Byrna Technologies Inc. (NASDAQ: BYRN) rose sharply during Friday’s session after the company reported better-than-ex...
TPST-1120, a first-in-class, oral, selective PPAR⍺ antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and ...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Tempest Therapeutics (NASDAQ:TPST) with a Buy and maintains $47 ...
Financial Results Year End 2023 Tempest ended the year with $39.2 million in cash and cash equivalents, compared to $31.2 m...
Scotiabank analyst George Farmer initiates coverage on Tempest Therapeutics (NASDAQ:TPST) with a Sector Outperform rating an...
Scotiabank analyst George Farmer initiates coverage on Tempest Therapeutics (NASDAQ:TPST) with a Sector Outperform rating an...